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Paroxysmal cold hemoglobinuria: a case report
S.C. Wise, S.H. Tinsley, and L.O. Cook
A 15-month-old white male child was admitted to the pediatric 
intensive care unit with symptoms of upper respiratory tract 
infection, increased somnolence, pallor, jaundice, fever, and 
decreased activity level. The purpose of this case study is to 
report the clinical findings associated with the patient’s 
clinical symptoms and differential laboratory diagnosis. 
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Case Report
A 15-month-old white male child was admitted to the 
pediatric intensive care unit with a several-day history of upper 
respiratory tract infection symptoms, followed by increased 
somnolence, pallor, jaundice, and fever. He was tachycardic 
with fever and pale, and he had a decreased activity level, 
jaundice, and bilateral otitis media. There was no past history 
of transfusion or hemoglobinuria.
The patient’s laboratory results were a hemoglobin level of 
4.4 g/dL, hematocrit of 13.2 percent, white blood cell (WBC) 
count of 21,000/µL (40 segmented neutrophils, 15 bands, 
35 lymphocytes, 7 monocytes, 2 eosinophils), red blood 
cell (RBC) count of 1.12 million/mm3, and platelet count of 
355,000/µL. The reticulocyte count was 1.5 percent (normal 
0.5 to 1 percent). Examination of the blood smear revealed 
poikilocytosis, spherocytosis, polychromasia, and nucleated 
RBCs. Small clumps of RBCs were also seen on the blood smear 
with the presence of erythrophagocytosis. Chemistry results 
revealed an indirect bilirubin of 3.8 mg/dL (0.6 to 10.5 mg/
dL), blood urea nitrogen of 14 mg/dL (5–30 mg/dL), creatinine 
of 0.3 mg/dL (0.5 to 1.5 mg/dL), and lactate dehydrogenase 
(LDH) of 578 IU/L (110–144 IU/L). A stat urine Gram’s stain 
was ordered, but no evidence of bacteria was reported. His 
urine was described as amber in color and clear with a trace of 
WBCs, squamous epithelium, and a small amount of bacteria 
and was positive for myoglobin. Urine chemistries showed 
elevated ketones, protein, and a small amount of blood. The 
patient was admitted with a diagnosis of acute intravascular 
hemolysis and possible pigment nephropathy and to rule out 
sepsis. He was started on oxygen by nasal cannula and given 
intravenous fluids at half maintenance rates with bicarbonate 
administered to alkalinize the urine to prevent crystallization 
of myoglobin or hemoglobin. His urine output was monitored, 
and fluids were given judiciously to prevent congestive heart 
failure. He was also started empirically on ceftriaxone. Blood 
and urine cultures were obtained and blood samples were 
sent to the blood bank for compatibility testing owing to the 
patient’s low hemoglobin level and symptomatic anemia.
Results
Blood bank serologic test results demonstrated the patient 
to be group O, D+. Results of antibody screening identified 
reactivity only after incubation at 37°C with low-ionic-strength 
saline (LISS). Six units were crossmatched, and all were found 
to be incompatible after incubation at 37°C with LISS. An 
initial antibody identification panel was performed. Reactions 
were only observed in the indirect antiglobulin test (IAT) 
after incubation at 37°C with LISS. There was no discernible 
specificity for the antibody. The patient’s autocontrol tube was 
also weakly positive after the incubation phase. At this point it 
was suspected that the patient might have a cold autoantibody, 
as the use of LISS can often enhance the reactivity of cold 
agglutinins. A cold antibody identification panel was performed 
using group O cells, adult I+, and adult ii cells. An autocontrol 
tube was also included. All cold panel cell tubes were found to 
be negative at immediate spin (IS) and after room temperature 
incubation with the exception of the patient autocontrol tube, 
which was weakly positive. The panel cells were incubated in 
the cold at 5°C. All of the cold panel cells were weakly reactive 
after incubation. A cold agglutinin titer was not performed 
because of the weak reactivity of the cold panel cells. The initial 
antibody identification panel was repeated using a polyspecific 
anti-human globulin (AHG) reagent. Results of the second 
antibody identification panel demonstrated reactivity only at 
the AHG phase of testing with a possible P1 specificity. The 
patient’s RBCs were also antigen tested and found to be P1+. 
Other clinically significant antibodies were ruled out using 
known typing antisera. Antigen testing was also performed on 
the incompatible donor units. Five of the six units were found 
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to be P1+. Additional crossmatched P1– units were found to be 
incompatible after incubation at 37°C with LISS. At this point 
the patient’s physician was contacted about the initial antibody 
workup results and the need to send specimens to a reference 
laboratory for further workup.   
Given the child’s symptoms and previous medical history 
(respiratory illness), hematology, blood bank, and chemistry 
test results, the patient’s physician, based on his own 
experience in treating pediatric patients with autoimmune 
hemolytic anemias (AIHA), suspected that the patient 
might have a rare condition known as paroxysmal cold 
hemoglobinuria (PCH). The physician requested that a cold 
direct antiglobulin test (DAT) be performed. Results of the 
cold DAT testing revealed strongly positive reactions (3+) with 
the polyspecific and the monospecific anti-C3d reagents but 
a negative reaction with the monospecific anti-IgG reagent. 
An elution was not performed as a result of lack of IgG coating 
the patient’s RBCs. To confirm whether this was actually 
a case of PCH, the Donath-Landsteiner (D-L) antibody 
test was performed. Results of the D-L test were positive, 
demonstrating the presence of a biphasic hemolysin. Units 
originally crossmatched were also tested by the D-L method, 
and all exhibited evidence of hemolysis after the incubation 
phase at 37°C. Introduction of polyspecific AHG reagent into 
compatibility testing procedures also showed the presence 
of only complement coating donor cells at the AHG phase of 
testing. At this point in the workup it was highly suspected 
that the specificity of the autoantibody was not anti-P1 but 
anti-P because of the biphasic hemolytic nature of the antibody 
and the fact that individuals of the P1 phenotype usually do 
not make anti-P1. The patient’s physician was contacted again 
about the need to send additional specimens to a reference 
laboratory for further testing. The patient’s physician declined 
to draw any more specimens from the child because of the low 
hemoglobin level.  
Focus was then shifted to finding compatible blood for 
the patient. The blood bank supervisor remembered that there 
was a large Amish community in Cleveland, Ohio, that would 
probably have P– blood. At this point, the American Red Cross 
(ARC) in Cleveland, Ohio, was contacted about the patient’s 
diagnosis and serologic status and the urgent need for blood 
transfusions. Three units of frozen P– RBCs were procured by 
the ARC in Cleveland, Ohio, and shipped to the blood bank. 
Segments were thawed, deglycerolized, and tested against 
the patient’s serum. All of the donor units were found to be 
compatible with the patient’s serum after incubation at 37°C 
with LISS using polyspecific AHG reagent and also by the D-L 
test method. Eight aliquots (~60 mL each) of deglycerolized 
RBCs were transfused within 12 hours of the patient’s 
admission with no adverse effects reported, and the patient’s 
hemoglobin level eventually stabilized at 13.0 g/dL.
Discussion
PCH is the rarest form of AIHA. It was first described in 
1845 in a patient who experienced an acute hemolytic episode 
associated with reddish-black urine after exposure to the cold.1 
In 1904, Donath and Landsteiner identified what they termed to 
be a “biphasic hemolysin” in blood that could be demonstrated 
in the laboratory.2 The antibody was demonstrated to bind to 
RBCs in vitro at low temperatures, activate complement, and 
produce RBC lysis after warming to 37°C. Historically, PCH 
has been linked to syphilis. The majority of cases involved 
chronic PCH in association with congenital syphilis.3 In 1954, 
PCH was identified in patients without syphilis and in children 
with febrile illness.4 In 1962, Dacie described PCH as having 
three distinct types: (1) chronic, syphilitic PCH (occurring 
in  late-stage syphilis); (2) congenital syphilis (occurring in 
children); and (3) nonsyphilitic PCH, which appears either 
as an acute transient form, usually viral related, or a chronic 
idiopathic or autoimmune form.5 Dacie concluded that the 
demographics of this disease changed in that the chronic 
syphilitic form of PCH had experienced a marked decline as a 
result of successful antibiotic therapy in treating patients with 
syphilis. Today, PCH occurs primarily in young children after 
a recent viral illness and is most often acute and transient.
Clinical Presentation
PCH can occur at any age. However, it tends to occur 
in young children after the onset of a recent respiratory or 
gastrointestinal tract infection. Typically, patients present 
with fever, chills, and abdominal, back, or leg pain, as well 
as hemoglobinuria after cold exposure.6 These symptoms 
are primarily seen in the chronic form of PCH. In the acute 
transient form of PCH, signs and symptoms generally include 
pallor, jaundice, fever, and hemoglobinuria.7,8 The peripheral 
blood smear typically exhibits evidence of hemolytic anemia 
(poikilocytosis, spherocytosis, polychromasia, and nucleated 
RBCs). There may also be significant agglutination as well as 
erythrophagocytosis. The presence of RBCs that have been 
engulfed by neutrophils is considered to be a distinguishing 
finding (not diagnostic) in the peripheral blood smear in 
patients with PCH.9 This finding has been shown to occur in 
about 20 percent of cases of PCH and 80 percent of cases of 
acute transient PCH in children.7 The reticulocyte count is often 
elevated but can vary with the hemolytic process. Hemoglobin 
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values tend to range anywhere from 2.5 to 12.5 g/L, with a 
mean value of 6.6 g/L.10 Significant laboratory chemistry 
results include an increased indirect bilirubin, increased LDH, 
and decreased serum haptoglobin. The color of the urine will 
depend on the amount of intravascular hemolysis, and it may 
vary from amber to dark reddish-black. The DAT will usually 
be positive only with anti-C3. The D-L antibody test will be 
positive, indicating the presence of a biphasic hemolysin.
Etiology
The exact etiology of PCH is unknown. The disease 
typically occurs after recent onset of viral or bacterial 
infection. Viral infections that have been implicated in PCH 
include varicella, measles, mumps, Epstein-Barr virus, 
cytomegalovirus, adenovirus, and influenza A.11,12 Organisms 
implicated in bacterial infections include Mycoplasma 
pneumoniae, Klebsiella pneumoniae, Escherichia coli, and 
Haemophilus influenzae.13 It has also been reported after 
vaccination for measles.14 The actual stimulus for PCH 
appears to be a form of molecular mimicry; that is, viral or 
bacterial antigens share a structural similarity with certain 
blood group system antigens found on human RBCs. As a 
result, the body mounts an autoimmune response, producing 
antibodies capable of binding with these blood group system 
antigens. In classic PCH, the specificity appears to be toward P. 
Autoantibodies to other blood group system antigens (e.g., A, I, 
i, and IH) have also been implicated in cases of PCH.15
Prevalence and Incidence
Most cases of PCH occur in young children. In 1989, 
Heddle reviewed previously published case reports on PCH 
in 42 pediatric patients with acute nonsyphilitic PCH.7 Heddle 
found that the mean age of diagnosis was 3.8 years, with a 
range from 15 months to 13 years. These findings were 
echoed in 1990 by Göttsche et al., who reviewed 22 cases of 
nonsyphilitic pediatric PCH.8 Göttsche et al. found that patient 
ages ranged from 8 months to 5.5 years, with a mean age of 
31 months. There is a mild male sex predilection with PCH; 
the male-to-female ratio is approximately 2:1 to 5:1.10 No racial 
predisposition has been recognized for PCH. Several studies 
have been performed to assess the incidence of PCH in adults 
and children. In 1981, Sokol et al. studied 865 cases of AIHA; 
17 (2%) were D-L antibody positive.11 Of these, 13 occurred in 
children younger than 10 years of age, 1 in a patient 32 years 
of age, and only 1 in a patient older than 40 years. All of the 
cases reviewed by Sokol et al. were described as being of the 
acute form with the exception of the one case occurring in the 
32-year-old. By 1984, Sokol et al. had investigated a total of 
42 cases of pediatric AIHA.16 They found that 17 (40%) were 
D-L antibody positive. They also reported two cases that 
occurred in adults having the D-L antibody, an acute form 
in a 62-year-old and a chronic idiopathic form in a 26-year-
old. In 1990, Göttsche et al. reviewed 599 cases of AIHA and 
found that 3.7 percent were D-L antibody positive.8 Of the 531 
adults, none had D-L antibody. Of the 68 children, 22 (32.4%) 
were D-L antibody positive. All 22 cases were described as 
being acute and transient. Issitt and Anstee have reported the 
overall incidence of PCH in the general population (adults and 
children) at about 1 in 600,000 to 1 in 800,000 per year, which 
accounts for less than 1 percent of all cases of AIHA.17
Pathophysiology
The autoantibody responsible for PCH is a biphasic 
hemolysin. The autoantibody binds to the patient’s own RBCs 
at lower temperatures (<30°C) in the body extremities and 
fixes complement. When the RBCs return to warmer areas 
of the body (37°C), complement is activated via the classical 
pathway, resulting in intravascular hemolysis. The antibody 
then elutes from the RBCs and returns to the circulation where 
it has the potential to again bind to RBCs at lower temperatures, 
causing additional paroxysms of hemolysis.
P1PK and Globoside Blood Group Systems
P1PK and Globoside are actually dual blood group 
systems. The P1PK system contains the P1 and Pk antigens and 
the Globoside system contains the P antigen. Together, the two 
systems define five different phenotypes. Table 1 summarizes 
the two blood group systems’ antigens and the antibodies that 
can be produced on inheritance of a particular phenotype.18 
The LKE phenotype does not appear in this table as it remains 
in the Globoside Collection. The LKE antigen is formed when 
two additional carbohydrate structures are added to the 
glycosphingolipid that carries Pk and P. Individuals who have 
Pk or P on their RBCs may be either LKE+ or LKE–.
Table 1. P1PK and Globoside Blood Group Systems*
Prevalence (%)
Phenotype Antibodies produced European African
P1 None 79 94
P2 Anti-P1 21 6
p Anti-PP1Pk (Tja) Rare Rare
P1k Anti-P Rare Rare
P2k Anti-P + Anti-P1 Rare Rare
*Adapted from The Blood Group Antigen FactsBook, 3rd ed. 2012.18
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Donath-Landsteiner Antibody Test
The confirmatory test for PCH is the D-L antibody test. To 
perform this test correctly, a serum sample is needed. Plasma 
cannot be used because the anticoagulant binds calcium, 
which is important to the complement cascade. Owing to the 
complement dependency of the autoantibody to demonstrate 
biphasic hemolysis, the serum sample must be fresh and kept 
at 37°C, and the serum must be separated from the clot at this 
temperature. The test is performed based on procedures found 
in the American Association of Blood Banks Technical Manual 
as follows:19
 1. Three sets of 10 × 75 mm tubes are labeled as follows: 
A1-A2-A3; B1-B2-B3; C1-C2-C3.
 2. Ten volumes of the patient’s serum are added to each 
tube 1 and 2 of each set.
 3. Ten volumes of fresh normal serum are added to each 
tube 2 and 3 of each set.
 4. One volume of 50 percent suspension of P+ RBCs is 
then added to each tube.
 5. The three “A” tubes are then placed in a bath of melting 
ice for 30 minutes and then at 37°C for 1 hour.
 6. The three “B” tubes are placed in a bath of melting ice 
and kept in the melting ice for 90 minutes.
 7. The three “C” tubes are placed at 37°C and kept at 
37°C for 90 minutes.
 8. At the end of the incubation periods, the tubes 
are gently mixed, centrifuged, and examined for 
hemolysis.
The D-L test is considered to be positive when the patient’s 
serum, with or without added complement, causes hemolysis 
in the tubes that were incubated first in the melting ice and 
then at 37°C and there is no hemolysis in any of the tubes 
maintained at 37°C or in the melting ice.
Results of the D-L testing for the patient in this case study 
are detailed in Table 2.
The D-L test does have some limitations in that it has 
a low sensitivity. Results are positive only when the serum 
antibody titer is high and the test is performed precisely. 
Falsely negative results may occur if there are low levels of 
antibody or complement present as a result of consumption 
during the hemolytic process in vivo. Falsely negative results 
may also occur if donor serum containing P or Pk is added as a 
source of complement as any globoside present may neutralize 
the D-L antibody.20
Differential Diagnosis
PCH can be confused with cold agglutinin syndrome 
(CAS) and warm autoimmune hemolytic anemia (WAIHA). 
Careful evaluation of serologic test results is necessary to 
obtain the correct diagnosis. Table 3 summarizes the serologic 
findings of all four categories of AIHA.21
Characterization of the immunoglobulin type as well as 
the thermal amplitude of the autoantibody or autoantibodies 
is important in obtaining the correct diagnosis. IAT and DAT 
test results must be carefully evaluated. If PCH is suspected, 
a D-L assay should be performed. If the D-L assay is positive, 
a diagnosis of PCH is confirmed. If the D-L antibody test 
is negative, other forms of AIHA should be investigated. 
Determination of the autoantibody specificity in AIHA is 
not always possible. In classic PCH, the autoantibody shows 
specificity for P. If P– RBCs are available, they can be tested 
against the patient serum. If the P– RBCs do not react, a 
specificity of autoanti-P is confirmed. If the P– RBCs react 
with the patient’s serum, alternative antibody specificities 
must be considered. Specificities to I, i, H, and IH have been 
reported in the literature.17
Conclusion and Treatment
The exact nature of the biphasic hemolysin in this case 
could not be fully determined. The autoantibody did appear 
to show P antigen specificity in the antibody identification 
studies that were performed. The patient’s typing results ruled 
out the possibility that the antibody specificity was directed 
toward the P1 antigen. P1+ individuals usually do not make 
antibodies toward P or GLOB blood group system antigens. 
However, there have been cases documented in the literature 
of autoanti-P1 causing in vitro hemolysis but not presenting 
as a biphasic hemolysin. The DAT was only positive with 
anti-C3, ruling out WAIHA and mixed-type AIHA as possible 
causes. Reactivity with anti-C3 was also shown to increase 
significantly after incubation in the cold. Antibody titers were 
not performed because of the weak reactivity of the cold panel 
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Table 2. Patient D-L antibody test results
Tube Melting ice, 30 min + 37°C, 1 hour Melting ice, 90 min 37°C, 90 min
A1 Positive with hemolysis
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cells. An elution was not performed because there was no 
detectable IgG coating the patient’s RBCs. The positive D-L 
antibody test coupled with the fact that only P– RBCs were 
compatible with the patient’s serum supports the explanation 
that this was a case of classic PCH involving autoanti-P. This 
D-L antibody was atypical: it displayed a broader thermal range 
than is usually seen in classic PCH. It was detectable only after 
incubation at 37°C with LISS and in the AHG phase of testing 
after the addition of polyspecific AHG reagent. Determining 
the specificity of autoagglutinins can be very time-consuming 
as well as expensive. This can be further complicated if the 
patient has been recently transfused. Most blood banks and 
transfusion services do not have the resources necessary to 
resolve such complex serologic problems. If AIHA is suspected 
and the patient has been recently transfused, samples should 
be sent to a reference laboratory for further serologic analysis.
The mainstay of treatment of PCH is to provide supportive 
care. As mentioned previously, this condition is usually 
acute and transient. If the anemia is mild and there is no 
renal involvement, hospitalization is usually not necessary. 
If the degree of anemia is severe, supportive care along with 
RBC transfusions may be warranted. In this particular case 
the anemia was quite severe, and the patient did require 
transfusions with several units of P– RBCs to stabilize his 
anemia and alleviate clinical symptoms. It was fortunate 
in this patient’s case that P– blood could be obtained. The 
prevalence of this phenotype is approximately 1 in 200,000 
and it may take several days to find the blood.18 Most patients 
with severe anemia cannot wait for this rare blood to be 
found. The AABB Technical Manual, 17th edition, makes the 
following recommendation regarding transfusion of suspected 
PCH patients: “Transfusion of random donor blood should not 
be withheld from PCH patients whose need is urgent. RBCs 
negative for P should be considered only for those patients 
who do not respond adequately to random donor blood.18 PCH 
patients should be kept in a warm environment to minimize 
the potential for D-L antibody binding and acute hemolysis. 
Wynn et al. recommends maintaining the patient’s room 
at 30°C until the hemoglobinuria subsides.22 RBCs and any 
other fluids given to the patient should also be warmed before 
infusion. If the PCH is recurrent or chronic, the patient should 
be given instructions to avoid cold exposure as much as 
possible.
The use of steroids in treating patients with PCH is 
controversial. There have been several large studies that 
have concluded that steroids are not beneficial and should be 
discontinued once a diagnosis of PCH is made.7,16 Other studies 
have suggested that steroids are effective in removing RBCs 
coated only with IgG, less effective in clearing RBCs coated 
with complement and IgG, and least effective in clearing 
RBCs coated with both IgM and complement.23 In 1971, Ries 
et al. reported a case of PCH in which the D-L antibody had 
an extremely high thermal range.24 The patient was initially 
treated with corticosteroids and the clinical symptoms 
improved. As soon as the corticosteroids were tapered off, the 
patient experienced recurrent hemolysis. Studies investigating 
the use of steroids concluded that their use should be reserved 
for patients who have recurrent PCH and cannot limit their 
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Table 3. Differential diagnosis in autoimmune hemolytic anemia
WAIHA CAS Mixed type PCH
Autoantibody IgG (rarely IgM or IgA) IgM IgG and clinically significant 
IgM
Biphasic IgG (D-L antibody)
Clinical presentation Variable; predominantly 
extravascular hemolysis
Mild anemia; hemagglutination 
and vascular obstruction; 
intravascular hemolysis may 
occur
Combined WAIHA and CAS; or 
WAIHA
Acute onset, severe anemia, 
intravascular hemolysis
DAT IgG (90% cases),  
alone or with C3;  
C3 alone (7% cases)
C3 alone (>90% cases) IgG and C3 (>70% cases) C3 alone (>95% cases)
Eluate Panreactive Nonreactive Panreactive Nonreactive
Antibody screen Panreactive (50% cases) Negative unless performed  
in cold
Panreactive Negative
Special studies Extended RBC phenotyping; 
serum adsorptions to investigate 
underlying alloantibodies
High titer (≥64), High thermal 
amplitude (≥30°C) IgM





Relative specificity for Rh 
antigens
Ii antigens P antigen
WAIHA = warm autoimmune hemolytic anemia; CAS = cold agglutinin syndrome; PCH = paroxysmal cold hemoglobinuria; DAT = direct antiglobulin test;  
RBC = red blood cell.
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cold exposure. Another drug that has been successfully used 
to treat PCH is rituximab.25 Rituximab’s mechanism of action 
targets the CD20 marker on B cells. B cells are removed, thus 
limiting antibody production. The use of rituximab has been 
found to be most effective in treating patients with refractory 
cold and warm AIHAs.26 Splenectomy has not been shown 
to be an effective form of treatment for PCH because the 
spleen plays no major role in the pathogenesis of intravascular 
hemolysis.24
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